Cargando…
Finafloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever
Finafloxacin is a novel fluoroquinolone with optimal antibacterial activity in low pH environments, therefore offering a therapeutic advantage over some traditional antibiotics, in treating bacterial infections associated with acidic foci. Coxiella burnetii, the causative agent of Q fever, is a bact...
Autores principales: | Hartley, M. Gill, Norville, Isobel H., Richards, Mark I., Barnes, Kay B., Bewley, Kevin R., Vipond, Julia, Rayner, Emma, Vente, Andreas, Armstrong, Stuart J., Harding, Sarah V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670379/ https://www.ncbi.nlm.nih.gov/pubmed/34917048 http://dx.doi.org/10.3389/fmicb.2021.760698 |
Ejemplares similares
-
Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei
por: Barnes, Kay B., et al.
Publicado: (2017) -
The Fluoroquinolone Finafloxacin Protects BALB/c Mice Against an Intranasal Infection With Francisella tularensis Strain SchuS4
por: Barnes, Kay B., et al.
Publicado: (2019) -
Efficacy of finafloxacin in a murine model of inhalational glanders
por: Barnes, Kay B., et al.
Publicado: (2022) -
In Vitro Activity of Finafloxacin against Panels of Respiratory Pathogens
por: Harding, Sarah V., et al.
Publicado: (2023) -
Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using In Vitro and In Vivo Models of Q Fever
por: Clay, K. A., et al.
Publicado: (2021)